Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials
Abstract Emerging retrospective and prospective studies indicate that immune checkpoint inhibitors (ICIs) can be safe and effective cancer treatments among people living with human immunodeficiency virus (PLWH), however this high-cancer-risk population has often been excluded from groundbreaking can...
Guardado en:
Autores principales: | Kruti B. Vora, Biagio Ricciuti, Mark M. Awad |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aa00c730570744ea8ce5a8e2f7a79e54 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021) -
A decade of immune-checkpoint inhibitors in cancer therapy
por: Caroline Robert
Publicado: (2020) -
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Pan Shen, et al.
Publicado: (2021) -
Indicators of responsiveness to immune checkpoint inhibitors
por: Bradley D. Shields, et al.
Publicado: (2017) -
Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Enriqueta Felip, et al.
Publicado: (2021)